HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of ...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global ...
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress ...
12d
I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly ...
ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial ...
Targeting two receptors instead of the one targeted by fezolinetant, the new elinzanetant did not show the liver safety ...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today a ...
AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024: Cambridge, UK Wednesday, September 4, 2024, 10:00 Hrs [IST] AstraZeneca ...
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback